Peter Corry
Concepts (460)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperthermia, Induced | 24 | 2012 | 118 | 2.090 |
Why?
| Heat-Shock Proteins | 16 | 2005 | 99 | 1.810 |
Why?
| Hot Temperature | 33 | 2012 | 208 | 1.600 |
Why?
| Radiotherapy, Intensity-Modulated | 10 | 2017 | 172 | 1.210 |
Why?
| Radiotherapy Planning, Computer-Assisted | 12 | 2017 | 247 | 1.040 |
Why?
| Antioxidants | 2 | 2020 | 248 | 0.930 |
Why?
| Radiometry | 8 | 2017 | 123 | 0.880 |
Why?
| Neoplasms | 19 | 2016 | 1233 | 0.820 |
Why?
| Tomography, Spiral Computed | 5 | 2017 | 56 | 0.750 |
Why?
| Radiation-Protective Agents | 3 | 2020 | 74 | 0.740 |
Why?
| Abdomen | 2 | 2011 | 79 | 0.730 |
Why?
| Gene Expression Regulation, Neoplastic | 12 | 2012 | 829 | 0.680 |
Why?
| Heart | 4 | 2013 | 326 | 0.650 |
Why?
| Radiotherapy | 4 | 2014 | 128 | 0.640 |
Why?
| Oxygen | 3 | 2012 | 325 | 0.630 |
Why?
| Radiotherapy, Image-Guided | 3 | 2016 | 23 | 0.600 |
Why?
| Pneumonia, Viral | 1 | 2020 | 168 | 0.570 |
Why?
| Radiation Injuries, Experimental | 6 | 2013 | 81 | 0.570 |
Why?
| Coronavirus Infections | 1 | 2020 | 178 | 0.560 |
Why?
| Organ Sparing Treatments | 3 | 2016 | 55 | 0.560 |
Why?
| Cell Survival | 26 | 2012 | 598 | 0.550 |
Why?
| Animals | 53 | 2021 | 13150 | 0.520 |
Why?
| Pandemics | 1 | 2020 | 554 | 0.510 |
Why?
| Mammary Neoplasms, Experimental | 3 | 2012 | 122 | 0.500 |
Why?
| Radiosurgery | 2 | 2016 | 117 | 0.490 |
Why?
| Organs at Risk | 3 | 2016 | 68 | 0.460 |
Why?
| Tumor Cells, Cultured | 24 | 2001 | 465 | 0.460 |
Why?
| Head and Neck Neoplasms | 3 | 2017 | 268 | 0.450 |
Why?
| HSP70 Heat-Shock Proteins | 6 | 2001 | 62 | 0.440 |
Why?
| Radiotherapy Dosage | 13 | 2017 | 243 | 0.430 |
Why?
| Peptides | 3 | 2012 | 222 | 0.430 |
Why?
| Radiation Injuries | 3 | 2013 | 113 | 0.420 |
Why?
| Ultrasonic Therapy | 5 | 2008 | 32 | 0.420 |
Why?
| Isoquinolines | 5 | 1996 | 25 | 0.420 |
Why?
| Galectin 1 | 1 | 2012 | 21 | 0.410 |
Why?
| Blood Vessels | 1 | 2012 | 72 | 0.400 |
Why?
| Protein Kinase C | 7 | 1996 | 71 | 0.390 |
Why?
| Molecular Targeted Therapy | 1 | 2012 | 119 | 0.390 |
Why?
| Piperazines | 5 | 1996 | 117 | 0.390 |
Why?
| Brain Neoplasms | 2 | 2012 | 286 | 0.380 |
Why?
| Bone and Bones | 2 | 2011 | 468 | 0.370 |
Why?
| Prostatic Neoplasms | 7 | 2017 | 396 | 0.370 |
Why?
| Myocardium | 4 | 2014 | 429 | 0.360 |
Why?
| Acetylcysteine | 2 | 2010 | 100 | 0.360 |
Why?
| Carcinoma, Squamous Cell | 2 | 2012 | 319 | 0.360 |
Why?
| Mice | 16 | 2021 | 5720 | 0.350 |
Why?
| Fibroblast Growth Factor 2 | 4 | 1999 | 34 | 0.350 |
Why?
| Cell Nucleus | 6 | 1996 | 184 | 0.340 |
Why?
| Sulfonamides | 3 | 1995 | 129 | 0.340 |
Why?
| Bone Density | 1 | 2011 | 379 | 0.330 |
Why?
| Image Processing, Computer-Assisted | 3 | 2017 | 241 | 0.330 |
Why?
| Nuclear Proteins | 4 | 1996 | 243 | 0.330 |
Why?
| Cerebellar Neoplasms | 2 | 2009 | 22 | 0.330 |
Why?
| Cranial Irradiation | 2 | 2009 | 21 | 0.330 |
Why?
| Combined Modality Therapy | 10 | 2012 | 636 | 0.320 |
Why?
| Cricetinae | 18 | 2021 | 192 | 0.310 |
Why?
| Humans | 63 | 2021 | 49827 | 0.310 |
Why?
| Heat-Shock Response | 2 | 2005 | 28 | 0.310 |
Why?
| Medulloblastoma | 1 | 2008 | 16 | 0.310 |
Why?
| Oxygen Consumption | 1 | 2009 | 180 | 0.310 |
Why?
| Sodium Compounds | 4 | 1994 | 11 | 0.300 |
Why?
| Arsenites | 4 | 1994 | 13 | 0.300 |
Why?
| Arsenic | 3 | 1991 | 24 | 0.280 |
Why?
| Whole-Body Irradiation | 3 | 2020 | 131 | 0.280 |
Why?
| Cell Hypoxia | 2 | 2012 | 82 | 0.270 |
Why?
| Radiobiology | 1 | 2005 | 21 | 0.270 |
Why?
| Breast Neoplasms | 9 | 2016 | 1169 | 0.260 |
Why?
| Medicine | 1 | 2005 | 56 | 0.250 |
Why?
| Quercetin | 3 | 1994 | 16 | 0.250 |
Why?
| Radiation Dosage | 7 | 2008 | 157 | 0.250 |
Why?
| Dose-Response Relationship, Radiation | 8 | 2012 | 184 | 0.250 |
Why?
| Rats | 17 | 2021 | 3300 | 0.250 |
Why?
| Cycloheximide | 8 | 1994 | 37 | 0.240 |
Why?
| Brain | 1 | 2012 | 1309 | 0.230 |
Why?
| Promoter Regions, Genetic | 5 | 2001 | 477 | 0.230 |
Why?
| Signal Transduction | 5 | 2013 | 1617 | 0.220 |
Why?
| Brachytherapy | 7 | 1998 | 48 | 0.220 |
Why?
| Tocotrienols | 2 | 2013 | 37 | 0.220 |
Why?
| Radiotherapy, Conformal | 2 | 2016 | 53 | 0.220 |
Why?
| Cell Line | 13 | 2005 | 1002 | 0.220 |
Why?
| Radiation Tolerance | 7 | 2013 | 84 | 0.220 |
Why?
| Gene Expression | 6 | 2012 | 608 | 0.220 |
Why?
| Neovascularization, Pathologic | 3 | 2012 | 161 | 0.210 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2000 | 156 | 0.210 |
Why?
| Paclitaxel | 2 | 2009 | 84 | 0.210 |
Why?
| Transcription Factor AP-1 | 3 | 1999 | 63 | 0.210 |
Why?
| Glucose | 4 | 2000 | 340 | 0.200 |
Why?
| Drug Resistance, Multiple | 6 | 2000 | 23 | 0.200 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.190 |
Why?
| CHO Cells | 8 | 1996 | 120 | 0.190 |
Why?
| Lung Neoplasms | 3 | 2017 | 605 | 0.180 |
Why?
| Time Factors | 13 | 2014 | 2912 | 0.180 |
Why?
| Angiogenesis Inhibitors | 2 | 2012 | 187 | 0.170 |
Why?
| Temperature | 8 | 2005 | 168 | 0.170 |
Why?
| Models, Biological | 3 | 2016 | 728 | 0.170 |
Why?
| Male | 23 | 2021 | 25093 | 0.170 |
Why?
| RNA, Messenger | 8 | 1999 | 1105 | 0.170 |
Why?
| Crystallins | 2 | 1996 | 12 | 0.170 |
Why?
| Carcinoma | 4 | 1999 | 137 | 0.160 |
Why?
| Base Sequence | 8 | 2009 | 650 | 0.160 |
Why?
| Molecular Sequence Data | 8 | 2009 | 797 | 0.150 |
Why?
| DNA-Binding Proteins | 4 | 1996 | 436 | 0.150 |
Why?
| Tomography, X-Ray Computed | 4 | 2016 | 1159 | 0.150 |
Why?
| MicroRNAs | 1 | 2021 | 354 | 0.150 |
Why?
| Adenoviridae | 4 | 2001 | 51 | 0.150 |
Why?
| Proteins | 3 | 2010 | 341 | 0.150 |
Why?
| Genes, bcl-2 | 1 | 1997 | 9 | 0.150 |
Why?
| Colonic Neoplasms | 8 | 1995 | 162 | 0.150 |
Why?
| Radiation-Sensitizing Agents | 2 | 2010 | 53 | 0.150 |
Why?
| Enzyme Inhibitors | 3 | 1996 | 391 | 0.150 |
Why?
| Rectum | 4 | 1998 | 54 | 0.140 |
Why?
| Genes, myc | 1 | 1997 | 40 | 0.140 |
Why?
| Esophageal Neoplasms | 1 | 1998 | 99 | 0.140 |
Why?
| Transcription Factors | 3 | 1996 | 563 | 0.140 |
Why?
| Calcitriol | 1 | 1996 | 36 | 0.140 |
Why?
| Kinetics | 7 | 1996 | 626 | 0.140 |
Why?
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 5 | 1996 | 7 | 0.140 |
Why?
| Radiation Protection | 2 | 2016 | 48 | 0.130 |
Why?
| Cell Line, Tumor | 4 | 2012 | 1402 | 0.130 |
Why?
| Mice, Inbred C57BL | 2 | 2011 | 1806 | 0.130 |
Why?
| Fourier Analysis | 1 | 1995 | 19 | 0.130 |
Why?
| Transcription, Genetic | 4 | 1999 | 371 | 0.130 |
Why?
| Craniospinal Irradiation | 1 | 2014 | 9 | 0.120 |
Why?
| Neoplasm Proteins | 2 | 1997 | 323 | 0.120 |
Why?
| Genetic Therapy | 3 | 2001 | 114 | 0.120 |
Why?
| Female | 28 | 2021 | 26329 | 0.120 |
Why?
| Phosphorylation | 5 | 2013 | 536 | 0.120 |
Why?
| Radiation Pneumonitis | 2 | 2016 | 9 | 0.120 |
Why?
| Equipment Design | 2 | 2012 | 282 | 0.120 |
Why?
| Harringtonines | 1 | 1993 | 3 | 0.120 |
Why?
| Phantoms, Imaging | 3 | 2011 | 120 | 0.120 |
Why?
| Apoptosis | 2 | 2014 | 1100 | 0.120 |
Why?
| Membrane Proteins | 1 | 1996 | 342 | 0.120 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 152 | 0.120 |
Why?
| Pentoxifylline | 1 | 2013 | 14 | 0.110 |
Why?
| Immunohistochemistry | 2 | 2013 | 971 | 0.110 |
Why?
| Microscopy, Fluorescence | 2 | 2009 | 162 | 0.110 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 1993 | 69 | 0.110 |
Why?
| Monte Carlo Method | 1 | 2013 | 84 | 0.110 |
Why?
| Radiography | 3 | 2009 | 489 | 0.110 |
Why?
| Oxidative Stress | 4 | 2012 | 768 | 0.110 |
Why?
| Kininogens | 1 | 2012 | 3 | 0.110 |
Why?
| Kallikrein-Kinin System | 1 | 2012 | 3 | 0.110 |
Why?
| Genetic Vectors | 4 | 2001 | 127 | 0.110 |
Why?
| Protein Biosynthesis | 2 | 1996 | 253 | 0.110 |
Why?
| Ablation Techniques | 1 | 2012 | 20 | 0.110 |
Why?
| Deuterium | 1 | 1992 | 42 | 0.110 |
Why?
| Tumor Burden | 2 | 2010 | 132 | 0.100 |
Why?
| Cisplatin | 4 | 2009 | 278 | 0.100 |
Why?
| 3T3 Cells | 4 | 1996 | 55 | 0.100 |
Why?
| Computer Simulation | 5 | 2016 | 282 | 0.100 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2011 | 183 | 0.100 |
Why?
| Bystander Effect | 1 | 2012 | 26 | 0.100 |
Why?
| Mitogen-Activated Protein Kinase 1 | 4 | 2013 | 51 | 0.100 |
Why?
| Oligodeoxyribonucleotides | 4 | 1996 | 31 | 0.100 |
Why?
| Carrier Proteins | 1 | 1993 | 304 | 0.100 |
Why?
| Adaptation, Physiological | 1 | 1992 | 91 | 0.100 |
Why?
| Myocarditis | 1 | 2012 | 42 | 0.100 |
Why?
| Transfection | 5 | 2000 | 357 | 0.100 |
Why?
| Models, Chemical | 2 | 2008 | 66 | 0.100 |
Why?
| Acclimatization | 1 | 1991 | 17 | 0.100 |
Why?
| Models, Theoretical | 1 | 2012 | 174 | 0.100 |
Why?
| Organ Specificity | 1 | 2011 | 108 | 0.100 |
Why?
| Nucleoside Deaminases | 3 | 2001 | 4 | 0.100 |
Why?
| Thymidine Kinase | 3 | 2001 | 19 | 0.090 |
Why?
| Cell Proliferation | 2 | 2012 | 1007 | 0.090 |
Why?
| Mitochondria | 1 | 2014 | 397 | 0.090 |
Why?
| Blotting, Western | 6 | 2012 | 602 | 0.090 |
Why?
| Leukocyte Count | 1 | 2010 | 70 | 0.090 |
Why?
| Malformations of Cortical Development | 1 | 2009 | 3 | 0.090 |
Why?
| Middle Aged | 9 | 2021 | 11997 | 0.090 |
Why?
| Drug Resistance, Neoplasm | 3 | 1997 | 308 | 0.090 |
Why?
| Cytokines | 1 | 1993 | 612 | 0.090 |
Why?
| Tubulin | 1 | 2009 | 22 | 0.090 |
Why?
| Genes, jun | 3 | 1999 | 21 | 0.090 |
Why?
| Optic Nerve Diseases | 1 | 2009 | 23 | 0.090 |
Why?
| Genes, fos | 3 | 1999 | 29 | 0.090 |
Why?
| Taxoids | 1 | 2009 | 37 | 0.090 |
Why?
| Carboplatin | 1 | 2009 | 53 | 0.080 |
Why?
| Fluorouracil | 1 | 2009 | 55 | 0.080 |
Why?
| Disease Progression | 1 | 2012 | 822 | 0.080 |
Why?
| Body Weight | 1 | 2011 | 513 | 0.080 |
Why?
| Information Systems | 1 | 1989 | 27 | 0.080 |
Why?
| Spinal Neoplasms | 1 | 2009 | 28 | 0.080 |
Why?
| Follow-Up Studies | 3 | 2009 | 2179 | 0.080 |
Why?
| Aged | 6 | 2021 | 9272 | 0.080 |
Why?
| Necrosis | 1 | 2009 | 177 | 0.080 |
Why?
| Bone Marrow | 3 | 2010 | 362 | 0.080 |
Why?
| Cell Death | 3 | 2005 | 181 | 0.080 |
Why?
| History, 20th Century | 1 | 2009 | 100 | 0.080 |
Why?
| Osteogenesis | 1 | 2011 | 351 | 0.080 |
Why?
| Carbon | 1 | 2008 | 55 | 0.080 |
Why?
| Cricetulus | 9 | 1990 | 97 | 0.080 |
Why?
| Gene Expression Regulation | 3 | 2021 | 979 | 0.080 |
Why?
| Weight Loss | 1 | 2010 | 239 | 0.080 |
Why?
| Reactive Oxygen Species | 1 | 2010 | 408 | 0.080 |
Why?
| Genes, Recessive | 2 | 2009 | 16 | 0.080 |
Why?
| Radiotherapy, Computer-Assisted | 1 | 2007 | 16 | 0.070 |
Why?
| Skull | 1 | 2007 | 75 | 0.070 |
Why?
| Adult | 8 | 2021 | 13160 | 0.070 |
Why?
| Ovary | 6 | 1990 | 104 | 0.070 |
Why?
| Central Nervous System Neoplasms | 1 | 2007 | 63 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 4 | 1995 | 1374 | 0.070 |
Why?
| Spine | 1 | 2007 | 94 | 0.070 |
Why?
| Fibrosarcoma | 3 | 2011 | 15 | 0.070 |
Why?
| Genetic Variation | 2 | 2009 | 214 | 0.070 |
Why?
| Cell Cycle | 3 | 1996 | 232 | 0.070 |
Why?
| Particle Accelerators | 2 | 2017 | 50 | 0.070 |
Why?
| Antineoplastic Agents | 2 | 1993 | 1172 | 0.070 |
Why?
| Mitosis | 2 | 1996 | 92 | 0.070 |
Why?
| Swine | 3 | 2012 | 391 | 0.060 |
Why?
| Blotting, Northern | 3 | 1996 | 109 | 0.060 |
Why?
| DNA Damage | 4 | 2012 | 301 | 0.060 |
Why?
| Rats, Sprague-Dawley | 3 | 2014 | 1595 | 0.060 |
Why?
| DNA Repair | 4 | 1988 | 192 | 0.060 |
Why?
| Ultrasonics | 2 | 1982 | 28 | 0.060 |
Why?
| DNA, Neoplasm | 2 | 1993 | 147 | 0.060 |
Why?
| Retrospective Studies | 3 | 2012 | 6117 | 0.060 |
Why?
| Antiviral Agents | 3 | 2021 | 174 | 0.060 |
Why?
| Flow Cytometry | 3 | 1996 | 470 | 0.060 |
Why?
| Aged, 80 and over | 3 | 2021 | 3125 | 0.060 |
Why?
| Treatment Outcome | 2 | 2012 | 5138 | 0.060 |
Why?
| Protein Synthesis Inhibitors | 2 | 1996 | 17 | 0.060 |
Why?
| Gene Transfer Techniques | 2 | 2001 | 37 | 0.060 |
Why?
| Cytomegalovirus | 2 | 2001 | 26 | 0.060 |
Why?
| Hydrogen-Ion Concentration | 3 | 1994 | 174 | 0.060 |
Why?
| Diathermy | 1 | 1983 | 1 | 0.060 |
Why?
| Mutation | 1 | 2009 | 1293 | 0.060 |
Why?
| Recombinant Proteins | 3 | 2000 | 486 | 0.060 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 987 | 0.060 |
Why?
| Magnetics | 1 | 1983 | 39 | 0.060 |
Why?
| X-Rays | 4 | 2016 | 55 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 50 | 0.050 |
Why?
| JNK Mitogen-Activated Protein Kinases | 2 | 2000 | 72 | 0.050 |
Why?
| Prodrugs | 2 | 2001 | 32 | 0.050 |
Why?
| Antigens, Differentiation, Myelomonocytic | 2 | 2013 | 39 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2002 | 18 | 0.050 |
Why?
| Flucytosine | 2 | 1999 | 14 | 0.050 |
Why?
| Antimetabolites | 2 | 1999 | 13 | 0.050 |
Why?
| Ganciclovir | 2 | 1999 | 24 | 0.050 |
Why?
| Genetic Markers | 1 | 2002 | 103 | 0.050 |
Why?
| Sensitivity and Specificity | 3 | 2009 | 854 | 0.050 |
Why?
| Microcephaly | 1 | 2002 | 41 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 6 | 0.050 |
Why?
| Antigens, CD | 2 | 2013 | 215 | 0.050 |
Why?
| Leucine | 2 | 1994 | 116 | 0.050 |
Why?
| Glycolysis | 1 | 2021 | 70 | 0.050 |
Why?
| ROC Curve | 1 | 2021 | 232 | 0.050 |
Why?
| Transgenes | 1 | 2001 | 55 | 0.050 |
Why?
| Genes, Reporter | 1 | 2001 | 89 | 0.050 |
Why?
| Luminescent Proteins | 1 | 2001 | 53 | 0.050 |
Why?
| Recombinant Fusion Proteins | 2 | 1999 | 182 | 0.050 |
Why?
| Green Fluorescent Proteins | 1 | 2001 | 90 | 0.050 |
Why?
| Algorithms | 2 | 2016 | 616 | 0.040 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 61 | 0.040 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 1999 | 75 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 3 | 1997 | 103 | 0.040 |
Why?
| Rabbits | 2 | 2010 | 370 | 0.040 |
Why?
| Child, Preschool | 4 | 2009 | 3853 | 0.040 |
Why?
| Linear Models | 2 | 2016 | 281 | 0.040 |
Why?
| Clinical Trials as Topic | 2 | 1991 | 460 | 0.040 |
Why?
| Proteomics | 1 | 2021 | 328 | 0.040 |
Why?
| Reproducibility of Results | 3 | 2009 | 1188 | 0.040 |
Why?
| Protein Kinase C-alpha | 2 | 2013 | 10 | 0.040 |
Why?
| Rectal Diseases | 1 | 1997 | 10 | 0.040 |
Why?
| Inflammation | 1 | 2021 | 604 | 0.040 |
Why?
| Nocodazole | 1 | 1996 | 4 | 0.040 |
Why?
| Protein Binding | 2 | 1996 | 660 | 0.040 |
Why?
| Cell Division | 2 | 1996 | 292 | 0.040 |
Why?
| Colony-Forming Units Assay | 1 | 1996 | 23 | 0.040 |
Why?
| Glioma | 3 | 1993 | 79 | 0.040 |
Why?
| Body Temperature | 2 | 1989 | 69 | 0.040 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 34 | 0.040 |
Why?
| Consanguinity | 2 | 2009 | 18 | 0.040 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 181 | 0.040 |
Why?
| Microtubules | 1 | 1996 | 41 | 0.040 |
Why?
| HSP30 Heat-Shock Proteins | 1 | 1996 | 1 | 0.040 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1996 | 46 | 0.030 |
Why?
| Receptors, Calcitriol | 1 | 1996 | 19 | 0.030 |
Why?
| Calorimetry, Differential Scanning | 1 | 1996 | 7 | 0.030 |
Why?
| Wound Healing | 1 | 1998 | 206 | 0.030 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 1996 | 7 | 0.030 |
Why?
| Nuclear Envelope | 1 | 1996 | 4 | 0.030 |
Why?
| Detergents | 1 | 1996 | 16 | 0.030 |
Why?
| Serum Albumin, Bovine | 1 | 1996 | 21 | 0.030 |
Why?
| DNA | 4 | 1988 | 545 | 0.030 |
Why?
| Microinjections | 1 | 1996 | 29 | 0.030 |
Why?
| Leukemia, Myeloid | 1 | 1996 | 44 | 0.030 |
Why?
| Permeability | 1 | 1996 | 68 | 0.030 |
Why?
| Isoenzymes | 1 | 1996 | 168 | 0.030 |
Why?
| Cone-Beam Computed Tomography | 1 | 2016 | 33 | 0.030 |
Why?
| Polymers | 1 | 1996 | 40 | 0.030 |
Why?
| Formaldehyde | 1 | 1996 | 52 | 0.030 |
Why?
| Solubility | 1 | 1996 | 68 | 0.030 |
Why?
| Poisson Distribution | 1 | 2016 | 34 | 0.030 |
Why?
| Quality Assurance, Health Care | 3 | 1991 | 149 | 0.030 |
Why?
| Cytosine Deaminase | 3 | 2001 | 8 | 0.030 |
Why?
| Probability | 1 | 2016 | 164 | 0.030 |
Why?
| Hypoglycemia | 1 | 1996 | 48 | 0.030 |
Why?
| Adolescent | 4 | 2009 | 6340 | 0.030 |
Why?
| G2 Phase | 1 | 1995 | 13 | 0.030 |
Why?
| Multiple Myeloma | 1 | 2010 | 2910 | 0.030 |
Why?
| Radio Waves | 1 | 1995 | 8 | 0.030 |
Why?
| Neoplasms, Experimental | 2 | 2009 | 114 | 0.030 |
Why?
| Thermodynamics | 1 | 1995 | 34 | 0.030 |
Why?
| Mathematics | 1 | 1995 | 45 | 0.030 |
Why?
| Child | 4 | 2009 | 6824 | 0.030 |
Why?
| Radiation, Ionizing | 1 | 1995 | 100 | 0.030 |
Why?
| Dimethyl Sulfoxide | 1 | 1994 | 12 | 0.030 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 18 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 38 | 0.030 |
Why?
| Gliosarcoma | 1 | 1994 | 5 | 0.030 |
Why?
| Cell Respiration | 1 | 2014 | 41 | 0.030 |
Why?
| HSC70 Heat-Shock Proteins | 1 | 1993 | 7 | 0.030 |
Why?
| Enzyme Activation | 3 | 2000 | 276 | 0.030 |
Why?
| bcl-2-Associated X Protein | 1 | 2014 | 56 | 0.030 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 1994 | 51 | 0.030 |
Why?
| Protein Conformation | 1 | 2014 | 166 | 0.030 |
Why?
| Software | 1 | 2016 | 273 | 0.030 |
Why?
| Cell Count | 1 | 2013 | 146 | 0.030 |
Why?
| Mast Cells | 1 | 2013 | 52 | 0.030 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 129 | 0.030 |
Why?
| Cells, Cultured | 4 | 1991 | 1571 | 0.030 |
Why?
| Cell Differentiation | 1 | 1996 | 653 | 0.030 |
Why?
| Drug Interactions | 1 | 2013 | 206 | 0.030 |
Why?
| Skin Temperature | 1 | 2012 | 15 | 0.030 |
Why?
| Mitochondrial Swelling | 1 | 2012 | 4 | 0.030 |
Why?
| Multigene Family | 1 | 1992 | 56 | 0.030 |
Why?
| Rats, Inbred BN | 1 | 2012 | 17 | 0.030 |
Why?
| Receptor, Bradykinin B2 | 1 | 2012 | 7 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 157 | 0.030 |
Why?
| DNA Probes | 1 | 1992 | 30 | 0.030 |
Why?
| Models, Animal | 1 | 2013 | 233 | 0.030 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.030 |
Why?
| Administration, Oral | 1 | 2013 | 423 | 0.030 |
Why?
| Up-Regulation | 1 | 2014 | 450 | 0.030 |
Why?
| Cell Fractionation | 1 | 1991 | 12 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2012 | 118 | 0.030 |
Why?
| Neck | 1 | 2012 | 99 | 0.020 |
Why?
| Burns | 2 | 2012 | 163 | 0.020 |
Why?
| Computer-Aided Design | 1 | 2011 | 21 | 0.020 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 45 | 0.020 |
Why?
| Endothelial Cells | 1 | 2013 | 269 | 0.020 |
Why?
| Heart Ventricles | 1 | 2013 | 248 | 0.020 |
Why?
| Evaluation Studies as Topic | 2 | 1988 | 106 | 0.020 |
Why?
| Partial Pressure | 1 | 2011 | 14 | 0.020 |
Why?
| Carbocyanines | 1 | 1990 | 6 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 595 | 0.020 |
Why?
| Molecular Weight | 1 | 1990 | 84 | 0.020 |
Why?
| Biological Transport | 1 | 1990 | 173 | 0.020 |
Why?
| Bone Transplantation | 1 | 2010 | 47 | 0.020 |
Why?
| Cell Transformation, Neoplastic | 1 | 2011 | 177 | 0.020 |
Why?
| HeLa Cells | 1 | 1990 | 251 | 0.020 |
Why?
| Pakistan | 1 | 2009 | 20 | 0.020 |
Why?
| Nuclear Family | 1 | 2009 | 15 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 179 | 0.020 |
Why?
| Feasibility Studies | 1 | 2011 | 374 | 0.020 |
Why?
| Pedigree | 1 | 2009 | 122 | 0.020 |
Why?
| Protein Isoforms | 1 | 2009 | 119 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 75 | 0.020 |
Why?
| Filing | 1 | 1989 | 1 | 0.020 |
Why?
| DNA, Single-Stranded | 3 | 1979 | 87 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Phenotype | 2 | 2002 | 727 | 0.020 |
Why?
| Syndrome | 1 | 2009 | 234 | 0.020 |
Why?
| Metaphase | 1 | 1968 | 44 | 0.020 |
Why?
| Chromosomes | 1 | 1968 | 33 | 0.020 |
Why?
| Escherichia coli | 2 | 2001 | 186 | 0.020 |
Why?
| Metals | 1 | 2008 | 34 | 0.020 |
Why?
| Acute Disease | 1 | 2009 | 369 | 0.020 |
Why?
| Glutathione | 2 | 2000 | 295 | 0.020 |
Why?
| Lung | 1 | 2011 | 480 | 0.020 |
Why?
| Liver | 2 | 2011 | 1109 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2009 | 485 | 0.020 |
Why?
| Survival Rate | 1 | 2009 | 905 | 0.020 |
Why?
| Kidney | 1 | 2011 | 665 | 0.020 |
Why?
| Skin | 1 | 2009 | 407 | 0.020 |
Why?
| Rats, Wistar | 2 | 1997 | 223 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 942 | 0.020 |
Why?
| Electrodes | 1 | 1984 | 36 | 0.020 |
Why?
| Microsatellite Repeats | 1 | 2002 | 37 | 0.010 |
Why?
| Medical Laboratory Science | 1 | 1982 | 2 | 0.010 |
Why?
| Crossing Over, Genetic | 1 | 1982 | 8 | 0.010 |
Why?
| Cystamine | 1 | 1982 | 2 | 0.010 |
Why?
| Cysteamine | 1 | 1982 | 7 | 0.010 |
Why?
| Sister Chromatid Exchange | 1 | 1982 | 15 | 0.010 |
Why?
| Gases | 1 | 1982 | 8 | 0.010 |
Why?
| Embryo, Mammalian | 1 | 1982 | 65 | 0.010 |
Why?
| Methods | 1 | 1981 | 55 | 0.010 |
Why?
| Thoracic Neoplasms | 1 | 1981 | 13 | 0.010 |
Why?
| Abdominal Neoplasms | 1 | 1981 | 17 | 0.010 |
Why?
| Pelvic Neoplasms | 1 | 1981 | 15 | 0.010 |
Why?
| Cell Adhesion | 1 | 1982 | 158 | 0.010 |
Why?
| Genes, p53 | 1 | 2001 | 51 | 0.010 |
Why?
| Intellectual Disability | 1 | 2002 | 124 | 0.010 |
Why?
| Cytarabine | 1 | 1981 | 39 | 0.010 |
Why?
| Clinical Protocols | 2 | 1991 | 108 | 0.010 |
Why?
| Mitomycins | 1 | 1980 | 2 | 0.010 |
Why?
| Dipeptides | 1 | 2000 | 21 | 0.010 |
Why?
| Cysteine | 1 | 2000 | 49 | 0.010 |
Why?
| Young Adult | 1 | 2009 | 3936 | 0.010 |
Why?
| Bleomycin | 1 | 1979 | 35 | 0.010 |
Why?
| Antimetabolites, Antineoplastic | 1 | 1999 | 37 | 0.010 |
Why?
| Gene Expression Regulation, Viral | 1 | 1999 | 48 | 0.010 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 1999 | 50 | 0.010 |
Why?
| Doxorubicin | 1 | 2000 | 230 | 0.010 |
Why?
| Herpesvirus 1, Human | 1 | 1998 | 15 | 0.010 |
Why?
| Glutathione Disulfide | 1 | 1998 | 41 | 0.010 |
Why?
| Colorectal Neoplasms | 1 | 2001 | 234 | 0.010 |
Why?
| HSP27 Heat-Shock Proteins | 1 | 1997 | 7 | 0.010 |
Why?
| Iridium Radioisotopes | 1 | 1997 | 3 | 0.010 |
Why?
| Neoplasm Transplantation | 1 | 1997 | 85 | 0.010 |
Why?
| Glutamic Acid | 1 | 1998 | 107 | 0.010 |
Why?
| Molecular Chaperones | 1 | 1997 | 64 | 0.010 |
Why?
| S Phase | 1 | 1996 | 19 | 0.010 |
Why?
| Mice, Nude | 1 | 1997 | 252 | 0.010 |
Why?
| Glutamine | 1 | 1998 | 171 | 0.010 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 1997 | 142 | 0.010 |
Why?
| DNA, Complementary | 1 | 1996 | 135 | 0.010 |
Why?
| Cytoplasm | 1 | 1996 | 90 | 0.010 |
Why?
| Adenocarcinoma | 1 | 1980 | 401 | 0.010 |
Why?
| Intestinal Obstruction | 1 | 1996 | 36 | 0.010 |
Why?
| Diarrhea | 1 | 1996 | 91 | 0.010 |
Why?
| Plasmids | 1 | 1996 | 159 | 0.010 |
Why?
| Infant, Newborn | 1 | 2002 | 2744 | 0.010 |
Why?
| Sodium Salicylate | 1 | 1994 | 4 | 0.010 |
Why?
| Cadmium Chloride | 1 | 1994 | 3 | 0.010 |
Why?
| Stimulation, Chemical | 1 | 1994 | 28 | 0.010 |
Why?
| Physical Stimulation | 1 | 1994 | 35 | 0.010 |
Why?
| Electrons | 1 | 1974 | 19 | 0.010 |
Why?
| Adaptation, Biological | 1 | 1994 | 10 | 0.010 |
Why?
| Cadmium | 1 | 1994 | 22 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1994 | 41 | 0.010 |
Why?
| Chlorides | 1 | 1994 | 51 | 0.010 |
Why?
| Infant | 1 | 2002 | 3551 | 0.010 |
Why?
| Stress, Physiological | 1 | 1994 | 170 | 0.010 |
Why?
| Disease Models, Animal | 1 | 1997 | 1451 | 0.010 |
Why?
| Equipment Safety | 1 | 1991 | 12 | 0.010 |
Why?
| Documentation | 1 | 1991 | 33 | 0.010 |
Why?
| Fibroblasts | 1 | 1993 | 343 | 0.010 |
Why?
| Histidinol | 1 | 1990 | 1 | 0.010 |
Why?
| Puromycin | 1 | 1990 | 3 | 0.010 |
Why?
| Electromagnetic Phenomena | 1 | 1988 | 5 | 0.000 |
Why?
| Drug Synergism | 1 | 1981 | 150 | 0.000 |
Why?
| Cross-Linking Reagents | 1 | 1980 | 44 | 0.000 |
Why?
| Remission, Spontaneous | 1 | 1979 | 24 | 0.000 |
Why?
| Creatine Kinase | 1 | 1979 | 29 | 0.000 |
Why?
| L-Lactate Dehydrogenase | 1 | 1979 | 65 | 0.000 |
Why?
| Tachycardia | 1 | 1979 | 29 | 0.000 |
Why?
| Etoposide | 1 | 1979 | 72 | 0.000 |
Why?
| Drug Therapy, Combination | 1 | 1980 | 378 | 0.000 |
Why?
| Peripheral Nervous System Diseases | 1 | 1979 | 57 | 0.000 |
Why?
| Neoplasm Metastasis | 1 | 1979 | 231 | 0.000 |
Why?
| Melphalan | 1 | 1979 | 174 | 0.000 |
Why?
| Electroencephalography | 1 | 1979 | 306 | 0.000 |
Why?
| Melanoma | 1 | 1979 | 284 | 0.000 |
Why?
| Relative Biological Effectiveness | 1 | 1974 | 8 | 0.000 |
Why?
| Centrifugation, Density Gradient | 1 | 1974 | 17 | 0.000 |
Why?
| Pregnancy | 1 | 1982 | 2584 | 0.000 |
Why?
| Gamma Rays | 1 | 1974 | 49 | 0.000 |
Why?
|
|
Corry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|